These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 17894827)

  • 21. Beneficial effect of atorvastatin on renal function in patients with type 2 diabetes.
    Tanaka M
    J Int Med Res; 2011; 39(4):1504-12. PubMed ID: 21986154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.
    Barter PJ; Rye KA; Tardif JC; Waters DD; Boekholdt SM; Breazna A; Kastelein JJ
    Circulation; 2011 Aug; 124(5):555-62. PubMed ID: 21804130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial.
    van Venrooij FV; van de Ree MA; Bots ML; Stolk RP; Huisman MV; Banga JD;
    Diabetes Care; 2002 Jul; 25(7):1211-6. PubMed ID: 12087021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy.
    Waters DD; Schwartz GG; Olsson AG; Zeiher A; Oliver MF; Ganz P; Ezekowitz M; Chaitman BR; Leslie SJ; Stern T;
    Circulation; 2002 Sep; 106(13):1690-5. PubMed ID: 12270864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
    Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Charlton-Menys V; DeMicco DA; Fuller JH;
    Am J Kidney Dis; 2009 Nov; 54(5):810-9. PubMed ID: 19540640
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Comparison of the effects of carbohydrate metabolism compensation and atorvastatin treatment on lipid metabolism and C-reactive protein in type 2 diabetes mellitus].
    Glinkina IV; Zilov AV; Mel'nichenko GA; Roĭtman AP; Il'in AV
    Ter Arkh; 2008; 80(12):17-22. PubMed ID: 19227901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus.
    Croom KF; Plosker GL
    Drugs; 2005; 65(1):137-52. PubMed ID: 15610062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.
    Deedwania P; Barter P; Carmena R; Fruchart JC; Grundy SM; Haffner S; Kastelein JJ; LaRosa JC; Schachner H; Shepherd J; Waters DD;
    Lancet; 2006 Sep; 368(9539):919-28. PubMed ID: 16962881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS).
    Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Thomason MJ; Fuller JH;
    Diabetologia; 2005 Dec; 48(12):2482-5. PubMed ID: 16284747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study.
    Goldstein LB; Amarenco P; Szarek M; Callahan A; Hennerici M; Sillesen H; Zivin JA; Welch KM;
    Neurology; 2008 Jun; 70(24 Pt 2):2364-70. PubMed ID: 18077795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus.
    Krane V; Winkler K; Drechsler C; Lilienthal J; März W; Wanner C;
    Am J Kidney Dis; 2009 Nov; 54(5):902-11. PubMed ID: 19781835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia.
    Gentile S; Turco S; Guarino G; Sasso CF; Amodio M; Magliano P; Salvatore T; Corigliano G; Agrusta M; De Simone G; Gaeta I; Oliviero B; Torella R
    Diabetes Obes Metab; 2000 Dec; 2(6):355-62. PubMed ID: 11225965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure.
    Sever PS; Poulter NR; Dahlof B; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes G; Mehlsen J; Nieminen MS; O'Brien ET; Ostergren J;
    Eur Heart J; 2008 Feb; 29(4):499-508. PubMed ID: 18175773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
    Sever PS; Poulter NR; Dahlof B; Wedel H;
    J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Callahan A; Amarenco P; Goldstein LB; Sillesen H; Messig M; Samsa GP; Altafullah I; Ledbetter LY; MacLeod MJ; Scott R; Hennerici M; Zivin JA; Welch KM;
    Arch Neurol; 2011 Oct; 68(10):1245-51. PubMed ID: 21670382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, double blind, placebo-controlled pilot trial of the safety and efficacy of atorvastatin in children with elevated low-density lipoprotein cholesterol (LDL-C) and type 1 diabetes.
    Canas JA; Ross JL; Taboada MV; Sikes KM; Damaso LC; Hossain J; Caulfield MP; Gidding SS; Mauras N
    Pediatr Diabetes; 2015 Mar; 16(2):79-89. PubMed ID: 25418907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
    Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
    J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study.
    Olsson AG; Eriksson M; Johnson O; Kjellström T; Lanke J; Larsen ML; Pedersen T; Tikkanen MJ; Wiklund O;
    Clin Ther; 2003 Jan; 25(1):119-38. PubMed ID: 12637115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Journal Watch: evidence that Atorvastatin reduces the risk of stroke and myocardial infarction in patients with type 2 diabetes, but with no evidence of dyslipidaemia.
    Gangaidzo IT
    Cent Afr J Med; 2005; 51(11-12):125-6. PubMed ID: 17447346
    [No Abstract]   [Full Text] [Related]  

  • 40. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).
    Neil HA; DeMicco DA; Luo D; Betteridge DJ; Colhoun HM; Durrington PN; Livingstone SJ; Fuller JH; Hitman GA;
    Diabetes Care; 2006 Nov; 29(11):2378-84. PubMed ID: 17065671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.